ReviewMenopause (New York, N.Y.)2019
Statin therapy: does sex matter?
Review in Menopause (New York, N.Y.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 29 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 4 syntheses or guidelines pooled it, 55 citations in OpenAlex.
- APOE genotype and the effect of statins on lipid outcomes: A meta-analysis.British journal of clinical pharmacology · 2026Pooled it
- Impact of statin use on breast cancer recurrence and mortality before and after diagnosis: a systematic review and meta-analysis.Frontiers in oncology · 2023Pooled it
- Medication Adherence After Acute Coronary Syndrome in Women Compared With Men: A Systematic Review and Meta-Analysis.Frontiers in global women's health · 2021Pooled it
- Reporting of sex as a variable in cardiovascular studies using cultured cells: A systematic review.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2020Pooled it
- No evidence of a detrimental effect of pitavastatin on neurocognitive function among people with HIV.AIDS (London, England) · 2025Trial
- Impact ofBiomedicines · 2026Article
- Sex differences in the treatment with PCSK9 monoclonal antibodies- real world experience from a dedicated preventive cardiology clinic.American journal of preventive cardiology · 2025Article
- Sex-specific formulations of doxazosin mesylate via direct powder extrusion 3D printing.Drug delivery and translational research · 2025Article
- Barriers and solutions in women's health research and clinical care: a call to action.Lancet regional health. Americas · 2025Review
- Article
- Exploring sex-based differences in patient outcomes: A secondary analysis of Heartwatch, an Irish cardiovascular secondary prevention programme.International journal of cardiology. Cardiovascular risk and prevention · 2025Article
- Nonadherence to Preventive Medications After Ischemic Stroke: Opportunities to Target Interventions by Sex, Race, and Ethnicity.Journal of the American Heart Association · 2024Article
- Genome-wide association study of therapeutic response to statin drugs in cardiovascular disease.Scientific reports · 2024Article
- Statin protects men but not women with HIV against loss of muscle mass, strength, and physical function: a pilot study.Scientific reports · 2023Article
- Cardiovascular disease preventive effects of aspirin combined with different statins in the United States general population.Scientific reports · 2023Article
- Cholesterol Management in Neurology: Time for Revised Strategies?Journal of personalized medicine · 2022Review
- Effect of Statins on Lung Cancer Molecular Pathways: A Possible Therapeutic Role.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Statins and cognition: Modifying factors and possible underlying mechanisms.Frontiers in aging neuroscience · 2022Review
- Real-world safety of PCSK9 inhibitors: A pharmacovigilance study based on spontaneous reports in FAERS.Frontiers in pharmacology · 2022Article
- Polymorphisms of the apolipoprotein E gene affect response to atorvastatin therapy in acute ischemic stroke.Frontiers in cardiovascular medicine · 2022Article
Corrections and comments
- Erratum issuedErratum.2021
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
Abstract
objectiveStatins are a class of drugs that competitively bind to the active site of HMG-CoA reductase enzyme, thereby inhibiting the initial steps in cholesterol synthesis. Originally approved for use in lowering serum cholesterol, a risk factor for developing atherosclerosis and coronary heart disease, statins have subsequently been noted to have myriad extrahepatic effects, including potential effects on cognition, diabetes, breast cancer, bone, and muscle. This narrative review assesses the current state of the science regarding the risks and benefits of statin therapy in women to identify areas where additional research is needed.
methodsBasic and clinical studies were identified by searching PubMed with particular attention to inclusion of female animals, women, randomized controlled trials, and sex-specific analyses.
resultsStatin therapy is generally recommended to reduce the risk of cardiovascular disease. None of the current clinical guidelines, however, offer sex-specific recommendations for women due to lack of understanding of sex differences and underlying mechanisms of disease processes. In addition, conclusions regarding efficacy of treatments do not consider lipid solubility for the drug, dosing, duration of treatment, interactions with estrogen, or comorbidities. Pleiotropic effects of statins are often derived from secondary analysis of studies with cardiovascular events as primary outcomes.
conclusionsMany of the trials that have established the efficacy and safety of statins were conducted predominantly or entirely in men, with results extrapolated to women. Additional research is needed to guide clinical recommendations specific to women. : Video Summary:http://links.lww.com/MENO/A462.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.